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Abstract
Background: Treatment of community acquired pneumonia (CAP) patients with antibiotics before laboratory-confirmed
diagnosis leads to loss of knowledge on the causative bacterial pathogen. Therefore, an increasing number of
pneumococcal infections is identified using non-culture based techniques. However, methods for serotyping
directly on the clinical specimen remain scarce. Here we present three approaches for detection and serotyping
of pneumococci using samples from patients with CAP.
Methods: The first approach is quantitative PCR (qPCR) analysis on blood samples (n = 211) followed by
capsular sequence typing (CST) to identify the serotype. The second approach, a urinary antigen assay (n = 223),
designated as inhibition multiplex immunoassay (IMIA), is based on Luminex technology targeting 14 serotypes.
The third approach is a multiplex immunoassay (MIA) (n = 171) also based on Luminex technology which
detects serologic antibody responses against 14 serotypes. The three alternative assays were performed on
samples obtained from 309 adult hospitalized CAP patients in 2007–2010 and the results were compared with
those obtained from conventional laboratory methods to detect pneumococcal CAP, i.e. blood cultures,
sputum cultures and BinaxNOW® urinary antigen tests.
Results: Using qPCR, MIA and IMIA, we were able to detect the pneumococcus in samples of 56% more patients
compared to conventional methods. Furthermore, we were able to assign a serotype to the infecting pneumococcus
from samples of 25% of all CAP patients, using any of the three serotyping methods (CST, IMIA and MIA).
Conclusion: This study indicates the usefulness of additional molecular methods to conventional laboratory methods
for the detection of pneumococcal pneumonia. Direct detection and subsequent serotyping on clinical samples will
improve the accuracy of pneumococcal surveillance to monitor vaccine effectiveness.
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Background
Streptococcus pneumoniae is a major human pathogen
causing considerable morbidity and mortality throughout
the world. It is considered the main cause of community
acquired pneumonia (CAP) [1,2], although there is little
consensus in the literature on the prevalence of pneumo-
cocci in CAP, it ranges from 10 to 48% in hospitalized
patients [1]. Differences are observed between countries
and health care settings, but also differences in methods
used to identify the causative agent contribute to the di-
verse numbers of prevalence [3,4]. The lack of sensitive
methods to identify the pathogen adds to the problem
[5-10]. Furthermore, patients are often treated with antibi-
otics before the collection of specimens for laboratory
diagnosis, making the identification of the causative agent
more problematic.
Standard microbiology assays to detect the pneumococ-
cus as the causative agent of CAP are culture from spu-
tum and/or blood, sputum gram stain and the BinaxNow
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S. pneumoniae test. The BinaxNow test is a rapid antigen
test on urine or cerebrospinal fluid, which detects
pneumococcal cell wall polysaccharides (CWPS). Spe-
cificity and sensitivity are high in adults for the diagno-
sis of pneumococcal CAP compared with conventional
methods [6,11,12]. In children, specificity is much lower
due to high carriage rates [5,13]. Developed assays for de-
tection of pneumococcal DNA in blood samples include
PCR and quantitative PCR (qPCR) [14-16]. Recently, a
few studies described the use of PCR to identify the sero-
type directly from pneumococcal DNA present in blood
[17-19]. These PCRs contain a myriad of primers and/or
probes, using single- or multiplex reactions, making the
method complex.
Currently, over 90 pneumococcal serotypes have been
described and roughly a quarter of these serotypes are
responsible for the majority of cases of invasive pneumo-
coccal disease (IPD) [20-24]. Serotyping of pneumococci
is essential in monitoring the effects of nationwide vac-
cine introduction. The classical technique for serotyping
is the Quellung reaction, based on reactivity of the cap-
sular polysaccharides with specific antisera [7,25]. To
identify a pneumococcal serotype using the Quellung re-
action, a cultured isolate must be present. The Quellung
reaction is time-consuming and expensive because a
whole collection of antisera is needed for the identifica-
tion of all serotypes. Many alternative serotyping methods
have been developed [17-19,26]. One of these is the
Capsular Sequence Typing (CST) [27,28], a method
based on the sequence obtained from a single PCR
product of the capsular gene wzh.
Measurement of serotype-specific antibodies has been
time-consuming due to the lack of multiplexing ability
of the Enzyme-linked immuno sorbent assay (ELISA).
With the introduction of the Luminex platform, simul-
taneous measurement of IgG concentrations directed
against a large number of different capsular polysaccha-
rides in a single assay became possible. This method was
first described by Pickering et al. for pneumococci [29]
and later adjusted and optimized by others [30,31]. In a
sandwich or inhibition version of the first described
pneumococcal Luminex assay, also detection of pneumo-
coccal polysaccharides in urine samples appeared to be
possible [10,32,33].
In this study, we describe three methods to assess the
pneumococcal serotype directly from urine and blood.
We developed an assay to conduct the serotyping by
CST directly on pneumococcal DNA isolated from blood
samples by a rapid extraction method. Furthermore, we
describe an inhibition assay approach to detect pneumo-
coccal capsular polysaccharides of 14 different serotypes
in urine. The serotypes covered by this assay represent
the serotypes in the 13-valent pneumococcal vaccine and
serotype 8 which is frequently found in IPD patients. The
third assay is previously described and detects the causative
pneumococcus by a positive antibody response [9]. The
methods are used to detect and serotype pneumococci in
CAP patients and the results from these assays are com-
pared with conventional microbiology assays.
Methods
Clinical samples
Blood and urine samples were obtained from hospital-
ized CAP patients aged 18 to 100 years, who participated
in a trial assessing the effect of dexamethasone use in
CAP. This study was carried out in the St. Antonius
Hospital, Nieuwegein, The Netherlands and is described
in detail elsewhere [34]. Mean age of the enrolled pa-
tients was 63 years old and approximately 27% of the pa-
tients started antibiotic treatment before enrolment.
Samples were collected from November 2007 to September
2010 and conventional laboratory methods to identify the
causative agent of CAP were performed. Additionally,
ethylenediamine-tetra-acetic acid (EDTA) blood samples for
molecular testing were obtained on the day of admission
and sent to the National Institute for Public Health and the
Environment (RIVM) within 1 day after the blood was
drawn. Urine samples for IMIA antigen testing were col-
lected on the day of admission, sent to the RIVM and stored
at −20°C until use. Serum samples for the detection of anti-
body responses by MIA were obtained on the day of admis-
sion and at day 30 after admission and stored at −80°C.
Eligible patients provided written informed consent and the
study was approved by the institutional Medical Ethics
Committee of the St. Antonius Hospital. This study was reg-
istered with ClinicalTrials.gov, number NCT00471640. For
comparison of the CST, serum samples and blood culture
isolates were collected from adults with pneumococcal
bacteremia hospitalized in a different institution between
December 2008 and June 2013.
Conventional laboratory methods
Diagnostic tests were performed on sputum, blood and
urine samples at the day of admission to identify the
causative agent of CAP as previously described [34].
Briefly, sputum samples were Gram stained and cultured
and at least two blood cultures were performed (BacT/
Alert; bioMérieux, Marcy l’Etoile, France). Urine samples
were used for detection of S. pneumoniae antigen (Binax-
NOW S. pneumoniae, Inverness Medical). The serotypes of
the pneumococcal isolates used for comparison of the CST
were determined by multiplex PCR analysis of the cps locus
as described by Pai et al. [26] or by Quellung reaction [25].
Molecular blood tests
Sample preparation
EDTA blood sample tubes were centrifuged for 10 mi-
nutes at 400×g. A milliliter of plasma was transferred to
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a clean tube and was centrifuged for 10 minutes at
14000xg. After transferring the plasma, the pellet was
centrifuged again for one minute at 14000xg and residual
plasma was discarded. From the pellet the pneumococcal
DNA was extracted using the Extract-N-Amp Plant PCR
Kit (Sigma-Aldrich, St. Louis, MO, USA). In detail, 25 μl
of extraction buffer was added to the pellet and incubated
at 95°C for 10 minutes. Thereafter, 25 μl of dilution buffer
was added and the material was ready for use in the qPCR.
For use in the CST, the samples were purified using a
Sephadex column (G-50, GE Healthcare, Chalfont St.
Giles, UK), according to manufacturer’s protocol.
From 200 μl serum samples used for comparison of
the CST, total DNA was extracted using the MagNA
Pure 96 Pathogen Universal 200 Kit (Roche Diagnostics,
Indianapolis, IN, USA) and eluted in 100 μl elution
buffer.
Detection qPCR
The quantitative PCR was based on two target genes, ply
and lytA, as described before [8,35]. Sequences of the
primers and probes are provided in Table 1. An internal
control was added to detect inhibitors of amplification
and contained a primer site for the lytA forward primer
and a primer site for the ply reverse primer. To amplify
the two gene segments, 10 μl PCR mixtures containing
QuantiTect Multiplex PCR NoROX Kit, (Qiagen, Hilden,
Germany), 0.6 μM of each primer, 0.3 μM of each probe,
1000 copies of internal control and 2 μl of the extracted
DNA were used. The PCR reaction was as follows: 2 min
50°C, 15 min 95°C and 40 cycles of 15 sec 95°C and 1 min
65°C in a LightCycler 480 (Roche, Mannheim, Germany).
The standard curve consisted of PCR products of ply and
lytA gene segments which were purified using Qiaquick
PCR Purification Kit (Qiagen) and quantified using a spec-
trophotometer (Nanodrop ND-1000, Thermo Scientific,
Wilmington, DE, USA). The PCR was considered positive
for pneumococci if at least one of the duplicate samples
yielded a fluorescent signal for lytA.
For comparison, the qPCR was performed by amplifi-
cation of a segment of the lytA gene only. The primer
and probe sequences were different from those applied
in the sample set of the general study (Table 1). The
25 μl PCR mix contained 1x TaqMan® Universal PCR
Master Mix, No AmpErase® UNG, 0.2 μM of each pri-
mer, 0.2 μM probe and 8 μl of the extracted DNA. Ther-
mal cycling was performed in a 7500 Fast Dx qPCR
Instrument (Applied Biosystems® Foster City, CA, USA)
with the following cycling conditions: 2 min 50°C, 10 min
95°C and 50 cycles of 15 sec 95°C and 1 min 60°C. The
standard curve consisted of a 10-fold dilution series of
genomic pneumococcal DNA extracted by the Qiagen
Genomic-tip 20/G Kit (Qiagen) and quantified by a spec-
trophotometer (Nanodrop ND-1000).
Capsular sequence typing (CST)
In CST a partial segment of the capsular gene wzh of the
pneumococcus is amplified and subsequently sequenced
[27]. Based on this sequence the capsular genotype is
assigned, designating the serotype. In this study, the
CST protocol was adapted to be performed directly on
blood plasma samples and serum. To enhance sensitivity,
the gene segment used in CST was amplified and se-
quenced in two overlapping segments which we subse-
quently assembled to create a single sequence. The primers
were designed with 5′-M13-tails to facilitate DNA sequen-
cing with a single M13 primer set (Table 1). To amplify the
Table 1 Oligonucleotide primers, probes and internal
control sequences
Assay Name Sequence
qPCR Sp-ply-531 F1 AGCGATAGCTTTCTCCAAGTGG
Sp-ply-583R1 CTTAGCCAACAAATCGTTTACCG
Sp-lytA-306 F1 ACGCAATCTAGCAGATGAAGC
Sp-lytA-386R1 TGTTTGGTTGGTTATTCGTGC
Sp-lytA-CDCF2 ACGCAATCTAGCAGATGAAGCA
Sp-lytA-CDCR2 TCGTGCGTTTTAATTCCAGCT
Sp-ply-556probe1 FAM-ACCCCAGCAATTCAAGTG
TTCGCG-BHQ1
Sp-lytA330-probe1 Cy5-TTTGCCGAAAACGCTTGA
TACAGGG-BHQ3
Sp-lytA-CDCprobe2 FAM-GCCGAAAACGCTTGATA
CAGGGAG-BHQ1
Sp-lytA-probe2 FAM-TTTGCCGAAAACGCTTGA
TACAGGG-TAMRA
Sp-Spike-qPCR3 ACGCAATCTAGCAGATGAAGC
TATCATGGCGACGTGTTTCATG
CAGATATATCGGTAAACGATTT
GTTGGCTAAG
Sp-spike-probe3 HEX-CATGGCGACGTGTTTCAT
GCAGATA-BHQ1
Clinical CST CST_01-M13F GTAAAACGACGGCCAGCATTC
GCATATCGTTTTTG
CST_03-M13F GTAAAACGACGGCCAGCATTC
GCACATCGTCTTTG
M13wzh1553F GTAAAACGACGGCCAGACCAT
TGTCTCTACCTCTCAC
M13wzh1553Fst3 GTAAAACGACGGCCAGATGAT
TGTGTCTACTTCGCAT
M13wzh1747R CAGGAAACAGCTATGACATCA
AGGCATAACGACTATCA
CST_01-M13R CAGGAAACAGCTATGACCTGA
GCTCTTTTTTTCATGA
CST_04-M13R CAGGAAACAGCTATGACCCGA
GCTCTCTTTTTCATGA
M13F GTAAAACGACGGCCAG
M13R CAGGAAACAGCTATGAC
1used in the general study [8,35].
2used in the comparison sample set [40].
3DNA sequence used for internal control of the qPCR.
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two gene segments 25 μl PCR mixtures containing Hotstar-
taq mix (Qiagen), 10 μM of each primer and 5 μl Sephadex
purified DNA template were used. The PCR reaction was
performed as follows: 15 min 95°C, 10 cycles of 20 sec
95°C, 30 sec 61-51°C and 30 sec 72°C followed by 35 cycles
of 20 sec 95°C and 1 min 72°C, followed by 7 min 72°C.
PCR products were purified using ExoSAP-IT (GE
Healthcare Life Sciences) according to the manufacturer’s
instructions. One μl aliquots of the purified PCR products
were used in sequence reactions with M13 forward and
reverse primers using Big Dye Terminator technology
(Applied Biosystems) on an AB 3730 genetic analyser.
Data analysis for CST was performed using Bionumerics
version 7.0 (Applied Maths, Sint-Martens-Latem, Belgium).
All sequences of the CST were assembled, edited, trimmed
and assigned a capsular type. A capsular type is a compos-
ite assignment; the first part of the assignment is based on
the phenotype assessed by conventional serotyping and the
second part of the assignment is the consecutive number
of the capsular type belonging to the same serotype. As an
example, CT09V-01 designated the first variant in wzh se-
quence of an isolate serotyped as 9V. The CST database is
publicly available through www.rivm.nl/mpf/spn/cst.
Inhibition multiplex immunoassay (IMIA) for
polysaccharide detection in urine
Urine samples were thawed and 2 ml urine was added to
2 ml absolute ethanol and incubated at 4°C overnight.
Samples were centrifuged for 15 min at 3200xg, super-
natant was discarded and the pellet was resolved in
100 μl PBS (pH 7.2) and heated for 10 min at 95°C. After
the samples were centrifuged for 15 min at 2000xg the
supernatant was stored at −20°C until use in the IMIA.
The coupling of the polysaccharides to carboxylated mi-
crospheres (Bio-Rad Laboratories, Hercules, CA, USA)
was performed as previously described [30,33]. Briefly,
purified capsular polysaccharides were conjugated to
Poly-L-Lysine. The conjugates were coupled to carbox-
ylated microspheres. All capsular polysaccharides were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA) except for polysaccharide
6A which was kindly provided by Pfizer Inc. (New York,
NY, USA). Type and factor rabbit sera were obtained from
Statens Serum Institut in Denmark and were purified
using Melon Gel IgG Purification Kit (Thermo Fisher
Scientific Inc., Rockford, IL USA) according to manu-
facturer’s protocol. The antisera against 14 serotypes
were pooled and incubated overnight at 4°C in adsorb-
ent buffer containing 15 μg/ml CWPS Multi and 5%
antibody depleted human serum (ADHS, Valley Biomedical,
Winchester, VA) in PBS (pH 7.2). The mixture contained
antisera in the following dilutions: serotype 9V, 1:300; sero-
types 6A, 6B, 8, 18C, 23F, 1:1,000; serotypes 3, 4, 1:1,600;
serotype 7F, 1:2,000; serotype 19A, 1:5,000; serotype 19F,
1:8,000; serotype 1, 1:10,000; serotype 14, 1:21,600 and
serotype 5, 1:150,000.
An aliquot of 25 μl of urine samples was incubated in
duplicate for 1 h at room temperature with 25 μl of the
pooled antiserum on a plate shaker. Subsequently, per
well 4000 beads of each serotype specific microsphere
set were added and incubated for 1 h at room temperature
on a plate shaker. After the microspheres were washed
using PBS-Tween, the beads were incubated for 20 min
at room temperature with 100 μl of a 1/200 dilution of
R-phycoerythrin-conjugated anti-rabbit IgG (Southern
Biotechnology, Birmingham, AL, U.S.A.). After another
wash of the microspheres, 125 μl PBS-Tween was
added and microspheres were analysed using the Bio-Plex
100 (Bio-Rad, Hertfordshire, United Kingdom). Detection
of polysaccharide in urine samples was considered positive
using a 30% positivity cut-off value from the mean median
fluorescent intensity (MFI) of duplicate pooled samples
without competitive inhibition. The intra-run reproduci-
bility was calculated as the coefficient of variation (CV) of
replicates and a CV of 10% was considered to be accept-
able. Polysaccharides of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8,
9V, 14, 18C, 19A, 19F and 23F were pooled and prepared
in 10-fold dilutions from 1000 ng/ml to 0.01 ng/ml in PBS
and were used as reference range in the assay.
Multiplex Immunoassay (MIA) for assessment of
longitudinal antibody concentrations
In two consecutive serum samples, an early (day 0–3)
and late (day 11–100) sample, pneumococcal antibody
concentrations were measured against 14 different sero-
types (1, 3, 4, 8, 9N, 12F, 14, 19F, 23F, 6B, 7F, 18C, 19A,
and 9V) using Luminex XMAP technology. Antibody
concentrations were calculated by interpolation from a
5-parameter logistic standard curve [36,37], plotting the
MFI against the polysaccharide concentration (Luminex
software). A positive antibody response was defined as a
serotype-specific twofold increase in antibody concentra-
tions between the two samples. This method is described
in more detail elsewhere [9].
Statistical analysis
Statistical tests were performed using Graphpad Quickcalc
software. Agreement between two tests was assessed by
Cohen’s kappa (κ) statistic, with values indicating poor
(0.00-0.20), fair (0.21 to 0.40), moderate (0.41-0.60), good
(0.61-0.80) and excellent agreement (0.81-1.00).
Results
Optimization and implementation of the qPCR, CST and
IMIA methods
Quantitative detection using qPCR was based on two
target genes, ply and lytA. Overall, the ply target yielded
amplification signals in more samples as compared to
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the lytA target indicating possible false positivity. There-
fore, a sample was considered positive for pneumococci
if at least one of the duplicate samples yielded a fluores-
cent signal for lytA. Based on serial dilutions of quantified
PCR products, the detection limit was estimated to be 1.6
gene copies per microliter extracted DNA per PCR. The
minimal bacterial load, determined using colony forming
units (CFU) dilution series, that could be detected in the
qPCR was 75 CFU per milliliter blood. Specificity of the
assay was high as genomic DNA of closely related Strepto-
cocci, including S. oralis, S. gordonii, S. parasanguinis,
S. sanguinis and S. mitis and S. mutans did not yield
PCR products. To determine which serotypes can be
detected using the primers amplifying the two overlap-
ping segments in CST, lysates of pneumococcal isolates
of the 45 serotypes most prevalent among IPD patients
in The Netherlands were tested. Only the isolates with
serotypes 10A, 22A, 23A, 24F, 25, 38 and 35B yielded
non-specific or no PCR products in 1 of the two PCRs.
The minimum amount of DNA required to perform
typing by CST was around 11 gene copies per PCR.
Once the assay was optimized, a comparison set of
serum samples from 19 pneumococcal CAP patients
were analysed by CST. In the serum samples with a
bacterial load of >1800 gene copies per ml serum, a
serotype could be identified by CST (Table 2). The se-
rotypes identified were serotype 3 (5x), 19A (2x), 7F
(2x), 4 (2x) and serotype 8 (1x) and there was full con-
cordance between CST on serum and Quellung reac-
tion and/or multiplex PCR on blood culture isolates.
Specificity of the IMIA was assessed with a mixture of
polysaccharide coated microspheres and pooled antisera,
spiked with polysaccharides from a single serotype for
inhibition. This method enabled the identification of all
serotypes with negligible cross reactivity. The minimal
required concentration of polysaccharides for the assay
was assessed using spiked polysaccharides in urine and
was between 1 and 10 ng/ml urine.
Comparison of qPCR, IMIA and MIA with the conventional
methods
A total of 309 patients were enrolled in this study and in
these patients the causative agent of CAP was investi-
gated using conventional microbiological methods. For
211 (68%) patients, blood was available for detection of
pneumococci by qPCR and CST was performed if the
samples were positive in the qPCR. The IMIA was per-
formed on urine of 223 (72%) of the enrolled CAP pa-
tients. The serologic antibody response was assessed on
samples of 171 (55%) patients. In 64 (21%) patients the
pneumococcus was identified as causative agent of CAP
by at least one conventional microbiological method:
blood culture (28/301, 9%), sputum culture (15/294, 5%)
and/or BinaxNOW urinary antigen test (52/307, 17%)
(Table 3). In total, 8% (16/211) of patients were positive
for pneumococcal infection using the qPCR, 17% (39/223)
of patients using the IMIA and 22% (37/171) using the
MIA for serologic antibody response. The different assays
respectively obtained sensitivity of 29% (13 samples were
qPCR positive of the 45 available samples for qPCR of pa-
tients that were positive by any of the conventional
methods, Table 3), 43% (IMIA; 20/47) and 40% (MIA;
19/48) of the pneumococcal pneumonia patients iden-
tified by conventional methods.
An additional 36 patients (56% increase, 100 patients
in total), who were not recognized as pneumococcal
CAP patients using the conventional methods, had a
positive result in any of the three alternative methods.
Four of these patients had a positive result in ≥2 of the
alternative test methods. For two patients, samples had a
positive result by CST and IMIA, and for two patients,
samples had a positive result by MIA and IMIA (data
not shown). The MIA and IMIA resulted in similar per-
centages of positive samples when conventional tests
were negative (MIA 15%, 18/123; IMIA 11%, 19/176).
The qPCR performed on blood samples detected lower
number of additional positives (2%, 3/166) (Table 3).
Comparing the results from the assays that make use
of the same clinical materials, in 20 patients for whom
Table 2 Serotypes and bacterial load assessed in the
comparison set (n = 19 samples of bacteremic patients)
Copies/ml serum Serotype by
Quellung/multiplex
PCR
Capsular type
by CST on serum
22319 4 04-01
16865 3 03-01
15933 19A 19A-01*
10243 19A 19A-01
9803 3 03-03
8260 3 03-01
5954 7 F 07 F-01
5767 8 08-01
5533 7 F 07 F-01
1961 4 04-0*
1852 3 03-0*
1804 3 03-03
670 NT no seq.
656 8 no seq.
155 5 no seq.
123 1 no seq.
122 8 no seq.
101 9 V no seq.
92 7 F no seq.
*Sequence <506 bp.
No seq., no sequence obtained or not possible to determine the serotype.
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blood culture was positive and material for qPCR was
available, 45% (9/20) yielded a positive qPCR (Table 3).
In contrast, in blood culture negatives, 2% (4/184) of the
samples were positive by qPCR. Antibody responses mea-
sured by MIA provided a similar number of positive results
compared to blood culture. 43% (9/21) Of the patients that
were found positive for pneumococci using blood culture,
showed an antibody response using MIA. Of BinaxNOW
positive patients, 41% (16/39) had a positive result in IMIA
as well. An additional 13% (23/184) of BinaxNOW negative
patients were tested positive by IMIA. Notably, if in a pa-
tient the pneumococcal infection was provisionally diag-
nosed by sputum culture (n = 15), the alternative tests
yielded the lowest number of positive tests. The IMIA
yielded the largest number of positives if sputum cultures
were negative (16% (32/204). Specificity of the assays were
84% (32/204; IMIA vs. Sputum culture) and up to 98%
(4/184; qPCR vs. blood culture). The cohens κ of agree-
ment between assays ranged from 0.083 (poor; Sputum
culture vs. IMIA) and 0.507 (moderate; Blood culture vs.
qPCR) and was on average 0.288 (fair agreement).
Serotypes deduced by alternative methods
The alternative methods enabled the identification of the
serotypes in samples from 25% of all CAP patients (68
of 278 samples assessed using any of the alternative
methods). In comparison, Quellung could have been
performed on the infecting pneumococcus of 14% of
patients (43 of 308 patients were found positive using
blood or sputum culture). There was good concordance
between the results obtained in the three methods. Sero-
types 3 and 8 were the most frequently identified
pneumococcal serotypes, each found in 15 patients
(22%) (Table 4). Serotype 1, 9 V and 7 F were detected
in samples from 7 (10%), 6 (9%) and 3 (4%) patients,
respectively. In samples from 16 of the 68 patients
(24%), two or more methods yielded identical serotypes.
Once, the identical serotype was detected in all three
different methods. In three cases, different methods
yielded conflicting results. However, in these cases
ambiguous IMIA results were included with weak
signals for multiple serotypes.
Discussion
In this study, samples from patients with CAP were used
to evaluate the sensitivity of detection of S. pneumoniae
with three different methods and to assess the added
value for serotyping by non-culture methods. The ad-
vantage of the methods described in this study is that
they can be used after antibiotic treatment and are time-
saving, as culturing is not required. To the best of our
knowledge, this is the first study that compares multiple
assays used for detection and serotyping of pneumococci
directly from clinical samples without the use of culture.
The results of the three alternative methods revealed
considerable overlap with the results of the conventional
methods. Using the alternative methods, we were able to
detect the pneumococcus in samples from 56% more pa-
tients compared to conventional methods, providing
there were no false positive samples. Furthermore, of all
patients with pneumonia, a pneumococcal serotype was
determined in 25% using PCR/CST, IMIA and MIA as
compared to 14% in which an isolate was available for
serotyping using conventional methods
In general, the sensitivities of the individual tests de-
scribed in this study are in line with similar assays devel-
oped by others. In our study, a number of samples were
not available for each test. If only the patients for whom
all tests were performed were included, sensitivity and
specificity were higher compared to the numbers pro-
vided here. However, numbers were small and therefore
we presented the data from the incomplete sampling.
In our study we enrolled patients with a pneumococcal
CAP and non-pneumococcal CAP. The non-pneumococcal
Table 3 Contribution of the alternative methods to the diagnosis of pneumococcal CAP
All conventional tests Blood culture BinaxNow Sputum culture
Total Pos N (%) Neg N (%) Pos N (%) Neg N (%) Nd N Pos N (%) Neg N (%) Nd N Pos N (%) Neg N (%) Nd N
Total 309 64 245 28 273 8 52 255 2 15 279 15
qPCR Pos 16 13 (29) 3 (02) 9 (45) 4 (2) 3 10 (29) 6 (3) 0 4 (33) 9 (5) 3
Neg 195 32 (71) 163 (98) 11 (55) 180 (98) 4 24 (71) 169 (97) 2 8 (67) 176 (95) 11
Nd 98 19 79 8 89 1 18 80 0 3 94 1
IMIA Pos 39 20 (43) 19 (11) 11 (55) 27 (14) 1 16 (41) 23 (13) 0 3 (38) 32 (16) 4
Neg 184 27 (57) 157 (89) 9 (45) 171 (86) 4 23 (59) 161 (86) 0 5 (62) 172 (84) 0
Nd 86 17 69 8 75 3 13 71 2 7 75 4
MIA Pos 37 19 (40) 18 (15) 9 (43) 26 (10) 2 13 (36) 23 (9) 1 6 (40) 23 (9) 8
Neg 134 29 (60) 105 (85) 12 (57) 230 (90) 4 23 (64) 222 (91) 1 9 (60) 232 (91) 5
Nd 138 16 125 7 17 2 16 10 0 0 24 2
Pos: positive, Neg: negative, Nd: not done/not available.
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CAP patients account for the controls and are used to calcu-
late specificity. However, it would have been valuable to in-
clude non-pneumonia patients for specificity calculations.
Conventional tests (blood cultures, sputum cultures and
BinaxNOW urinary antigen test) lack sensitivity and are
therefore a far from ideal golden standard for specificity cal-
culations. Positive results in the investigated assays for pa-
tients with negative results in the conventional tests should
not be regarded as false-positive.
In a study by Abdeldaim et al., in CAP patients, the
percentages (9%) of lytA PCR positive samples was com-
parable, but sensitivity of the lytA PCR compared to
blood culture was slightly higher [38]. Cremers et al.
showed a considerable higher number of qPCR positives
(68%) in adults with blood-culture proven pneumococcal
CAP [16]. In a study by Marchese et al., the sensitivity
of the qPCR compared to blood culture was consider-
ably higher, but this study included only pediatric pa-
tients [17]. In pediatric patients the blood culture
positivity rate is considerably lower, which may be ex-
plained by lower bacterial load in children and small
sample volumes of pediatric patients [39]. Also, differ-
ences in the amount of template DNA and number of
PCR cycles could account for the differences in sensitiv-
ity between these studies. Also, primers used in these
studies differed from our study. These factors may influ-
ence the sensitivity. The detection limit of the qPCR de-
scribed here is comparable to the proposed CDC
method, both <10 copies per PCR reaction [40]. In the
comparison set as well as the general study, above a spe-
cific pneumococcal density threshold CST on clinical
specimens from CAP patients was successful and accur-
ate, despite differences in study region, cohort character-
istics, clinical specimen, extraction method and qPCR
conditions. The qPCR used in this study is based on the
previously published qPCRs, described by McAvin et al.
for lytA [8] and Greiner et al. for ply [35]. Other detec-
tion qPCR for pneumococci have been proposed, target-
ing these or other genes [40-42]. The lytA gene has been
showed to be highly specific [40], whereas the ply gene
is also carried by other flora normally present in the re-
spiratory tract, such as S. mitis and S. oralis, and therefore
may produce false positives in detection of pneumococci
[40,42,43]. The ply target was amplified in more samples
compared to the lytA target, indicating the non-specificity
of the ply gene and indicating the correct choice of lytA as
the primary target for the detection of pneumococci. The
same was described in the study of Palmu et al. [42]. In
our study, 69% of the blood samples with positive result in
the qPCR could be assigned a serotype using CST. In the
study by Marchese et al., molecular serotyping directly on
blood was successful in 36 of the 46 (80%) samples from
pediatric patients infected by pneumococci confirmed by
culture and/or molecular test (real-time PCR amplifica-
tion of both lytA and cpsA genes) [17]. In another study,
in 73 of the 80 qPCR positive blood samples a serotype
could be detected from patients of 0–16 years of age using
specific PCRs to detect 21 different serotypes [18]. The
Table 4 Distribution of serotypes in this study detected by CST, MIA and IMIA
Serotypes Frequency1 Percent CST (number
tested: n = 16)
MIA (number
tested: n = 171)
IMIA (number
tested: n = 223)
3 15 22 3 6 11
8 15 22 1 10 8
1 7 10 4 2 6
9V 6 9 1 2 4
7F 3 4 0 4 0
19A 2 3 0 2 1
4 2 3 1 3 0
6B 2 3 1 2 1
12F 1 1 0 1 NA
14 1 1 0 3 0
18C 1 1 0 1 0
23F 1 1 0 0 1
6A 1 1 0 NA 1
9N 1 1 0 1 NA
Ambiguous2 10 15 6
Total 68 100 11 37 39
1Number of the patients infected with a given serotype detected by any of the methods.
2No serotype could be determined because of cross reactivity with multiple serotypes in the IMIA or ambiguous results between methods.
NA. not applicable, serotype could not be assessed using the method.
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CST has proven to be a valuable method to assess the sero-
type of an isolate in over 3000 isolates [27,28] (www.rivm.
nl/mpf/spn/cst). Also, the method is quick and easy to
perform. Because this method is based on a single gene
in the capsular gene locus, some serotypes cannot be
distinguished, eg. serotypes 18B and 18C. In general,
one of the serotypes with corresponding sequence is
not common in invasive pneumococcal disease, such
as serotype 18B, but we are currently improving this
assay to enable differentiation between those serotypes.
Because the PCR target of the CST was divided in 2
segments to improve sensitivity, some serotypes could
no longer be detected by this technique. However, the
undetectable serotypes (serotypes 10A, 22A, 23A, 24F
25, 38, 35B) accounted for approximately 4% of IPD
after vaccine introduction (data annual report of Dutch
pneumococcal surveillance). Therefore, the increase in
sensitivity caused by the amendment of the original
assay outweighed the loss of the detection of these se-
rotypes for the Dutch situation. However, in other
parts of the world these serotypes may have increased
after vaccine implementation [44].
The inhibition multiplex immunoassay (IMIA) described
here detects the 13 serotypes included in PCV13 and sero-
type 8, because of the high incidence of invasive disease
caused by this serotype. A similar assay was described by
Findlow et al. with comparable sensitivity and specificity
[33]. Main differences were the use of CPS multi as a sor-
bent and the use of rabbit antisera instead of a reference
serum with a limited supply. In a different study using the
Luminex platform, a serotype detection system was devel-
oped in an antigen capture approach. This assay uses
monoclonal antibodies coupled to the microspheres and
polysaccharide is detected in urine with the use of poly-
clonal anti-polysaccharide antibodies [10]. The authors
showed a high specificity, which was supposed to be a
benefit from the use of monoclonal antibodies. In an
immune-inhibition approach like our method, commer-
cially available antiserum is used. The use of commercially
available antisera provides the possibility to expand the
assay easily to detect more serotypes. Specificity and sensi-
tivity in the study by Pride et al. were calculated using
samples from patients of which the serotype of the
pneumococcus was known to be a serotype that can be
detected by the used assay, in contrast to our study.
Therefore the accuracy of the tests cannot be com-
pared correctly. In our study no samples were available
for validation of the urinary assays such as the com-
parison set of blood samples. Although this is a draw-
back of the study, the good concordance of serotypes
between the different assays indicates the correct as-
signment of serotypes.
Serotype distribution in our study was comparable to the
serotype prevalence recorded by our national surveillance
system on IPD [45]. In other studies targeting CAP pa-
tients, serotype distribution was also similar, although sero-
type 19A is increasingly detected in studies conducted a
few years after introduction of pneumococcal conjugate
vaccine [46]. Furthermore, distribution of serotypes is
dependent on geography. For instance, in contrast to our
study, serotype 5 was detected in CAP studies in the USA
and UK [46,47]. Serotype 5 is mainly found in outbreaks in
Europe [48]. Of note, the serotypes that are detected in
surveillance studies will depend on the methods used. For
example, urinary antigen assays are often detecting only 13
or 14 serotypes [10,32]. PCRs performed on blood samples
to assign a serotype detect more serotypes, but this is also
limited [17,18,46].
Conclusion
In this study we assessed the use of three additional
methods to identify and concurrently serotype a pneumo-
coccus infecting patients hospitalized with CAP. Using
these methods, we detected the pneumococcus in samples
from 56% more patients compared to those found based
on conventional methods. Also, we were able to assign a
serotype to the infecting pneumococcus from samples of
25% of the patients using any of the three methods, com-
pared to 14% of isolates obtained by blood and sputum
culture suitable to determine the serotype by Quellung.
This study indicates the usefulness of additional molecular
methods to conventional laboratory methods for the de-
tection of pneumococcal pneumonia. Moreover, detection
of pneumococcal serotypes directly from clinical samples
may improve the surveillance of the pneumococcal vac-
cine effectiveness.
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